FDA approves new kind of cholesterol pill

The FDA's approval of Merck's Lipfendra marks a significant milestone in cholesterol management, offering a new PCSK9 inhibitor to help lower LDL cholesterol levels. This approval is crucial as high cholesterol is a major risk factor for heart disease, which remains a leading cause of death worldwide. With this new option, patients now have an additional tool to help manage their heart health more effectively, potentially reducing the incidence of cardiovascular events and improving overall quality of life for those at risk.